DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 6,000 shares of the stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $69.77, for a total transaction of $418,620.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Kevin R. Sayer also recently made the following trade(s):
- On Wednesday, July 12th, Kevin R. Sayer sold 6,000 shares of DexCom stock. The stock was sold at an average price of $71.86, for a total transaction of $431,160.00.
- On Monday, June 12th, Kevin R. Sayer sold 6,000 shares of DexCom stock. The stock was sold at an average price of $69.07, for a total transaction of $414,420.00.
Shares of DexCom, Inc. (DXCM) opened at 72.78 on Friday. The firm has a 50-day moving average of $70.65 and a 200 day moving average of $74.95. The firm’s market cap is $6.30 billion. DexCom, Inc. has a 12 month low of $57.68 and a 12 month high of $96.38.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The business had revenue of $170.60 million for the quarter, compared to the consensus estimate of $166.54 million. During the same period last year, the business earned ($0.24) EPS. The firm’s revenue was up 24.3% compared to the same quarter last year. On average, equities research analysts anticipate that DexCom, Inc. will post ($0.77) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “DexCom, Inc. (DXCM) CEO Sells $418,620.00 in Stock” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/08/18/dexcom-inc-dxcm-ceo-sells-418620-00-in-stock.html.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of DexCom during the first quarter worth $136,000. Advisor Group Inc. increased its position in shares of DexCom by 104.9% in the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after buying an additional 837 shares during the last quarter. IFP Advisors Inc increased its position in shares of DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock worth $158,000 after buying an additional 159 shares during the last quarter. Edmond DE Rothschild Holding S.A. bought a new position in shares of DexCom during the first quarter worth $164,000. Finally, Mn Services Vermogensbeheer B.V. increased its position in shares of DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock worth $179,000 after buying an additional 83 shares during the last quarter.
Several research analysts have recently weighed in on DXCM shares. Canaccord Genuity reiterated a “buy” rating and set a $90.00 price objective on shares of DexCom in a report on Wednesday, June 7th. Oppenheimer Holdings, Inc. set a $98.00 target price on shares of DexCom and gave the stock a “buy” rating in a research report on Wednesday, May 3rd. Piper Jaffray Companies reissued an “overweight” rating and set a $78.00 target price on shares of DexCom in a research report on Monday, May 22nd. BidaskClub raised shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. Finally, TheStreet raised shares of DexCom from a “d” rating to a “c-” rating in a research report on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $87.00.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
What are top analysts saying about DexCom Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DexCom Inc. and related companies.